Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC

It becomes the second KRAS-targeted therapy for use in patients with non–small cell lung cancer (NSCLC) whose tumors have this mutation.

Related Keywords

Shirishm Gadgeel , ,Department Of Internal Medicine ,Drug Administration ,Division Of Hematology ,Agilent Resolution ,Internal Medicine ,Henry Ford Cancer ,Henry Ford Health ,David Meek ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Skras ,K Ras ,V Ki Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog ,Gtpase Kras ,Biologic Therapy ,Colorectal Cancer ,Small Cell Lung Cancer ,Targeted Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Tumor ,Pain Management ,Lung ,Abdominal Pain ,Grant ,Spain ,Plasma ,Tissue ,Constipation ,Diarrhea ,Pneumonia ,